The Unitaid-funded ASCENT project aims to help patients succeed in TB treatment using digital adherence technology

Tuberculosis (TB) is still the deadliest infectious disease worldwide, killing over 4.000 people every day. This is unnecessary as TB can be cured with appropriate treatment. A number of barriers however, prevent patients from recovering from this disease, including long and complicated treatment regimens that involve the daily intake of medicines over the course of 6-24 months.

By leveraging today’s smart information and (mobile) communication technologies the ASCENT project (Adherence Support Coalition to End TB) aims to support TB patients with their treatment in a modern and more effective way through the use of digital adherence technologies such as smart pill boxes, medication sleeves and video supported treatment.

By generating evidence, establishing a global market and engaging stakeholders, ASCENT aims to make future scale up possible so that these digital innovations can be available to all TB patients worldwide.

news & Stories


Successful randomization ceremony in Ethiopia


Alex, 35 years, a miner and TB patient in Tanzania, was enrolled on 99DOTS digital adherence technology. Since the start of his treatment, he takes his medication daily. “It made my treatment easier and I wish the same for others.”

Why adherence to treatment is so important

Problem statement:

Missing doses of medication during tuberculosis treatment has serious negative effects
Patients are more likely to stop their TB treatment
Patients can develop resistance to anti TB drugs
Patients are more likely to get TB again

what is Tuberculosis?

Funding & support

Consortium partners

Funding & Support

Consortium partners

more about the ascent project

Sign up to our newsletter